| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H20NO2 |
| Molecular Weight | 174.2606 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O
InChI
InChIKey=UQOFGTXDASPNLL-XHNCKOQMSA-N
InChI=1S/C9H20NO2/c1-7-9(11)5-8(12-7)6-10(2,3)4/h7-9,11H,5-6H2,1-4H3/q+1/t7-,8-,9+/m0/s1
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Sample Use Guides
toxicity in mice: the mouse i.v. LD50 for muscarine chloride was calculated to be 0.23 mg/kg and for acetylcholine chloride 33.05 mg/kg, thus muscarine was 143 times more toxic than acetylcholine. Signs of poisoning were similar, acetylcholine being lethal almost immediately and muscarine after 3 to 10 min. Death never occurred later than 10 min after the injection.
Route of Administration:
Intravenous
Muscarine (1-30 microM) produced a dose-dependent hyperpolarization in a subpopulation of the nucleus raphe magnus (NRM) cells that contain 5-hydroxytryptamine (5-HT). In voltage clamp, the muscarine-induced outward current reversed polarity at the potassium equilibrium potential and was characterized by strong inward rectification. The concentration-response curve for muscarine (EC50 = 2.7 microM) was shifted in a parallel manner to the right by increasing concentrations of pirenzepine (300 nM to 3 microM) and methoctramine (50-200 nM).
SUBSTANCE RECORD
